SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

Home・Stock List・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Closed

SectorFinance

181.4 3.54

Buy Sell

Overview

Share price change

24h

Current

Min

181.4

Max

183.3

Key metrics
By Trading Economics
Income	41M 88M
Sales	-11M 762M
P/E Sector Avg	62.036 58.051
EPS	1.17
Profit margin	11.569
Employees	10,456
EBITDA	26M 225M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+33.37% upside

Dividends
By Dow Jones
Next Earnings	23 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-1.6B 17B
Previous open	177.86
Previous close	181.4

News Sentiment

By Acuity

21%

79%

30 / 438 Finance

Sartorius Stedim Biotech. Chart

Past performance is not a reliable indicator of future results.

Related News

29 May 2026, 23:08 UTC

Acquisitions, Mergers, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 May 2026, 23:06 UTC

Acquisitions, Mergers, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 May 2026, 20:53 UTC

Earnings

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 May 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29 May 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 May 2026, 20:11 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 May 2026, 19:47 UTC

Earnings

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 May 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 May 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 May 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 May 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 May 2026, 19:05 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 May 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 May 2026, 18:12 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 May 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 May 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 May 2026, 17:55 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 May 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29 May 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 May 2026, 17:00 UTC

Earnings

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 May 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29 May 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29 May 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 May 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 May 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

29 May 2026, 15:55 UTC

Market Talk

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 May 2026, 15:50 UTC

Acquisitions, Mergers, Takeovers

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 May 2026, 15:50 UTC

Acquisitions, Mergers, Takeovers

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 May 2026, 15:40 UTC

Market Talk

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 May 2026, 15:20 UTC

Market Talk

Canada's Economy Not Looking All That Bright -- Market Talk

Peer Comparison

Price change

Sartorius Stedim Biotech. Forecast

Price Target

By TipRanks

33.37% upside

12 Months Forecast

Average 233 EUR 33.37%

High 262 EUR

Low 210 EUR

Based on 8 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Sartorius Stedim Biotech. - Dist in the past 3 months.

Sentiment

By Acuity

30 / 438 Finance

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.